Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Every-12-hour administration of extended-release divalproex in patients with epilepsy: impact on plasma valproic acid concentrations.

Reed RC, Dutta S, Cavanaugh JH, Locke C, Granneman GR.

Epilepsy Behav. 2006 Mar;8(2):391-6.

PMID:
16473558
2.
3.

Are bioequivalence studies of levothyroxine sodium formulations in euthyroid volunteers reliable?

Blakesley V, Awni W, Locke C, Ludden T, Granneman GR, Braverman LE.

Thyroid. 2004 Mar;14(3):191-200.

PMID:
15072701
4.

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.

Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK.

Clin Ther. 2003 Jun;25(6):1700-21.

PMID:
12860493
5.

Oral/intravenous maintenance dosing of valproate following intravenous loading: a simulation.

Dutta S, Cloyd JC, Granneman GR, Collins SD.

Epilepsy Res. 2003 Feb;53(1-2):29-38.

PMID:
12576165
6.

Valproate unbound fraction and distribution volume following rapid infusions in patients with epilepsy.

Cloyd JC, Dutta S, Cao G, Walch JK, Collins SD, Granneman GR; Depacon Study Group.

Epilepsy Res. 2003 Feb;53(1-2):19-27.

PMID:
12576164
7.

Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients.

Hsu A, Isaacson J, Brun S, Bernstein B, Lam W, Bertz R, Foit C, Rynkiewicz K, Richards B, King M, Rode R, Kempf DJ, Granneman GR, Sun E.

Antimicrob Agents Chemother. 2003 Jan;47(1):350-9.

8.

Single- and multiple-dose pharmacokinetics of fiduxosin under nonfasting conditions in healthy male subjects.

Dutta S, Zhang Y, Daszkowski DJ, Granneman GR, Verlinden M.

J Clin Pharmacol. 2002 May;42(5):540-6.

PMID:
12017348
9.

Multiple dose pharmacokinetics of fiduxosin under fasting conditions in healthy elderly male subjects.

Dutta S, Zhang Y, Daszkowski DJ, Granneman GR, Verlinden M.

J Pharm Pharmacol. 2002 May;54(5):641-7.

PMID:
12005359
10.

Effect of food on the pharmacokinetics of fiduxosin in healthy male subjects.

Dutta S, Zhang Y, Granneman GR, Verlinden M.

Eur J Drug Metab Pharmacokinet. 2002 Jan-Mar;27(1):49-52.

PMID:
11996327
11.

Single-dose pharmacokinetics of atrasentan, an endothelin-A receptor antagonist.

Samara E, Dutta S, Cao G, Granneman GR, Dordal MS, Padley RJ.

J Clin Pharmacol. 2001 Apr;41(4):397-403.

PMID:
11304896
12.

Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction.

Kumar GN, Dykstra J, Roberts EM, Jayanti VK, Hickman D, Uchic J, Yao Y, Surber B, Thomas S, Granneman GR.

Drug Metab Dispos. 1999 Aug;27(8):902-8.

PMID:
10421617
13.
14.

Lack of a clinically significant pharmacokinetic drug interaction between tiagabine and valproate.

Gustavson LE, Sommerville KW, Boellner SW, Witt GF, Guenther HJ, Granneman GR.

Am J Ther. 1998 Mar;5(2):73-9.

PMID:
10099041
15.

ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease.

Sham HL, Kempf DJ, Molla A, Marsh KC, Kumar GN, Chen CM, Kati W, Stewart K, Lal R, Hsu A, Betebenner D, Korneyeva M, Vasavanonda S, McDonald E, Saldivar A, Wideburg N, Chen X, Niu P, Park C, Jayanti V, Grabowski B, Granneman GR, Sun E, Japour AJ, Leonard JM, Plattner JJ, Norbeck DW.

Antimicrob Agents Chemother. 1998 Dec;42(12):3218-24.

16.

Effect of fluoxetine on pharmacokinetics of ritonavir.

Ouellet D, Hsu A, Qian J, Lamm JE, Cavanaugh JH, Leonard JM, Granneman GR.

Antimicrob Agents Chemother. 1998 Dec;42(12):3107-12.

17.

Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents.

Hsu A, Granneman GR, Bertz RJ.

Clin Pharmacokinet. 1998 Oct;35(4):275-91. Review. Erratum in: Clin Pharmacokinet 1998 Dec;35(6):473.

PMID:
9812178
18.

Pharmacokinetic interaction between ritonavir and clarithromycin.

Ouellet D, Hsu A, Granneman GR, Carlson G, Cavanaugh J, Guenther H, Leonard JM.

Clin Pharmacol Ther. 1998 Oct;64(4):355-62.

PMID:
9797791
19.

Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers.

Hsu A, Granneman GR, Cao G, Carothers L, Japour A, El-Shourbagy T, Dennis S, Berg J, Erdman K, Leonard JM, Sun E.

Antimicrob Agents Chemother. 1998 Nov;42(11):2784-91.

20.

Recent developments in HIV protease inhibitor therapy.

Molla A, Granneman GR, Sun E, Kempf DJ.

Antiviral Res. 1998 Jul;39(1):1-23. Review. No abstract available.

PMID:
9754946
21.

Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers.

Ouellet D, Hsu A, Qian J, Locke CS, Eason CJ, Cavanaugh JH, Leonard JM, Granneman GR.

Br J Clin Pharmacol. 1998 Aug;46(2):111-6.

22.

Population analysis of the pharmacokinetics of tiagabine in patients with epilepsy.

Samara EE, Gustavson LE, El-Shourbagy T, Locke C, Granneman GR, Sommerville KW.

Epilepsia. 1998 Aug;39(8):868-73.

23.

Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir.

Hsu A, Granneman GR, Cao G, Carothers L, el-Shourbagy T, Baroldi P, Erdman K, Brown F, Sun E, Leonard JM.

Clin Pharmacol Ther. 1998 Apr;63(4):453-64.

PMID:
9585800
24.

Lack of CYP3A inhibition effects of sertindole on terfenadine in healthy volunteers.

Wong SL, Cao G, Mack R, Granneman GR.

Int J Clin Pharmacol Ther. 1998 Mar;36(3):146-51.

PMID:
9562230
25.

The effect of erythromycin on the CYP3A component of sertindole clearance in healthy volunteers.

Wong SL, Cao G, Mack RJ, Granneman GR.

J Clin Pharmacol. 1997 Nov;37(11):1056-61.

PMID:
9505999
26.

Lack of multiple dosing effect of sertindole on the pharmacokinetics of alprazolam in healthy volunteers.

Wong SL, Locke C, Staser J, Granneman GR.

Psychopharmacology (Berl). 1998 Feb;135(3):236-41.

PMID:
9498726
27.

Population analysis of the pharmacokinetics and pharmacodynamics of seratrodast in patients with mild to moderate asthma.

Samara E, Cao G, Locke C, Granneman GR, Dean R, Killian A.

Clin Pharmacol Ther. 1997 Oct;62(4):426-35.

PMID:
9357394
28.

Pharmacokinetics of sertindole in healthy young and elderly male and female subjects.

Wong SL, Cao G, Mack RJ, Granneman GR.

Clin Pharmacol Ther. 1997 Aug;62(2):157-64.

PMID:
9284851
29.

Effects of food, antacid, and dosage form on the pharmacokinetics and relative bioavailability of sertindole in healthy volunteers.

Wong SL, Linnen P, Mack R, Granneman GR.

Biopharm Drug Dispos. 1997 Aug;18(6):533-41.

PMID:
9267685
30.

Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects.

Hsu A, Granneman GR, Witt G, Locke C, Denissen J, Molla A, Valdes J, Smith J, Erdman K, Lyons N, Niu P, Decourt JP, Fourtillan JB, Girault J, Leonard JM.

Antimicrob Agents Chemother. 1997 May;41(5):898-905.

31.

A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures.

Gustavson LE, Boellner SW, Granneman GR, Qian JX, Guenther HJ, el-Shourbagy T, Sommerville KW.

Neurology. 1997 Apr;48(4):1032-7.

PMID:
9109895
32.

Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Bertz RJ, Granneman GR.

Clin Pharmacokinet. 1997 Mar;32(3):210-58. Review.

PMID:
9084960
33.

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.

Kempf DJ, Marsh KC, Kumar G, Rodrigues AD, Denissen JF, McDonald E, Kukulka MJ, Hsu A, Granneman GR, Baroldi PA, Sun E, Pizzuti D, Plattner JJ, Norbeck DW, Leonard JM.

Antimicrob Agents Chemother. 1997 Mar;41(3):654-60.

34.

Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety.

Tamminga CA, Mack RJ, Granneman GR, Silber CJ, Kashkin KB.

Int Clin Psychopharmacol. 1997 Feb;12 Suppl 1:S29-35. Review.

PMID:
9179641
35.

Pharmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal function.

Wong SL, Menacherry S, Mulford D, Schmitz PJ, Locke C, Granneman GR.

Eur J Clin Pharmacol. 1997;52(3):223-7.

PMID:
9218930
36.

Assessment of the pharmacokinetic-pharmacodynamic interaction between terazosin and finasteride.

Samara EE, Hosmane B, Locke C, Eason C, Cavanaugh J, Granneman GR.

J Clin Pharmacol. 1996 Dec;36(12):1169-78.

PMID:
9013375
37.

Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics.

Wong SL, Cavanaugh J, Shi H, Awni WM, Granneman GR.

Clin Pharmacol Ther. 1996 Jul;60(1):48-53.

PMID:
8689811
38.

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir.

Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper PJ, Mo HM, Markowitz M, Chernyavskiy T, Niu P, Lyons N, Hsu A, Granneman GR, Ho DD, Boucher CA, Leonard JM, Norbeck DW, Kempf DJ.

Nat Med. 1996 Jul;2(7):760-6.

PMID:
8673921
39.

Pharmacokinetic interactions and side effects resulting from concomitant administration of lithium and divalproex sodium.

Granneman GR, Schneck DW, Cavanaugh JH, Witt GF.

J Clin Psychiatry. 1996 May;57(5):204-6.

PMID:
8626351
40.

Pharmacokinetic interaction between lansoprazole and theophylline.

Granneman GR, Karol MD, Locke CS, Cavanaugh JH.

Ther Drug Monit. 1995 Oct;17(5):460-4.

PMID:
8585108
41.

The Effects of Lansoprazole on the Disposition of Antipyrine and Indocyanine Green in Normal Human Subjects.

St Peter JV, Awni WM, Granneman GR, Karol MD.

Am J Ther. 1995 Aug;2(8):561-568.

PMID:
11854827
42.

Determination of lansoprazole and five metabolites in plasma by high-performance liquid chromatography.

Karol MD, Granneman GR, Alexander K.

J Chromatogr B Biomed Appl. 1995 Jun 9;668(1):182-6.

PMID:
7550976
43.

The effect of zileuton on antipyrine and indocyanine green disposition.

St Peter JV, Braeckman RA, Granneman GR, Locke CS, Cavanaugh JH, Awni WM.

Clin Pharmacol Ther. 1995 Mar;57(3):299-308.

PMID:
7697947
44.
45.

Assessment of the pharmacokinetic interaction between zileuton and digoxin in humans.

Awni WM, Hussein Z, Cavanaugh JH, Granneman GR, Dubé LM.

Clin Pharmacokinet. 1995;29 Suppl 2:92-7.

PMID:
8620677
46.

Lack of pharmacokinetic interaction between zileuton and phenytoin in humans.

Samara E, Cavanaugh JH, Mukherjee D, Granneman GR.

Clin Pharmacokinet. 1995;29 Suppl 2:84-91.

PMID:
8620675
47.

Effect of zileuton on theophylline pharmacokinetics.

Granneman GR, Braeckman RA, Locke CS, Cavanaugh JH, Dubé LM, Awni WM.

Clin Pharmacokinet. 1995;29 Suppl 2:77-83.

PMID:
8620674
48.

Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans.

Awni WM, Hussein Z, Granneman GR, Patterson KJ, Dubé LM, Cavanaugh JH.

Clin Pharmacokinet. 1995;29 Suppl 2:67-76.

PMID:
8620673
49.

The effect of food on the pharmacokinetics of zileuton.

Awni WM, Cavanaugh JH, Witt G, Granneman GR, Dubé LM.

Clin Pharmacokinet. 1995;29 Suppl 2:62-6.

PMID:
8620672
50.

The effect of mild or moderate hepatic impairment (cirrhosis) on the pharmacokinetics of zileuton.

Awni WM, Cavanaugh JH, Braeckman RA, Chu SY, Patterson KJ, Machinist JM, Granneman GR.

Clin Pharmacokinet. 1995;29 Suppl 2:49-61.

PMID:
8620671

Supplemental Content

Loading ...
Support Center